These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31136371)

  • 1. Clinical Features of Rituximab-associated Gastrointestinal Toxicities.
    Mallepally N; Abu-Sbeih H; Ahmed O; Chen E; Shafi MA; Neelapu SS; Wang Y
    Am J Clin Oncol; 2019 Jun; 42(6):539-545. PubMed ID: 31136371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy.
    Tang T; Abu-Sbeih H; Ma W; Lu Y; Luo W; Foo WC; Richards DM; Halperin DM; Ge PS; Wang Y
    Clin Colorectal Cancer; 2020 Sep; 19(3):e117-e123. PubMed ID: 32284253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.
    Abu-Sbeih H; Ali FS; Luo W; Qiao W; Raju GS; Wang Y
    J Immunother Cancer; 2018 Sep; 6(1):95. PubMed ID: 30253811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of colitis induced by taxane-based chemotherapy.
    Chen E; Abu-Sbeih H; Thirumurthi S; Mallepally N; Khurana S; Wei D; Altan M; Morris VK; Tan D; Barcenas CH; Wang Y
    Ann Gastroenterol; 2020; 33(1):59-67. PubMed ID: 31892799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy.
    Abu-Sbeih H; Mallepally N; Goldstein R; Chen E; Tang T; Dike UK; Al-Asadi M; Westin S; Halperin D; Wang Y
    J Cancer; 2020; 11(11):3144-3150. PubMed ID: 32231718
    [No Abstract]   [Full Text] [Related]  

  • 6. Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy.
    Park SY; Kim MY; Choi WJ; Yoon DH; Lee SO; Choi SH; Kim YS; Suh C; Woo JH; Kim SH
    Med Mycol; 2017 Jun; 55(4):349-357. PubMed ID: 28339533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-related luminal GI adverse events.
    Kröner PT; Mody K; Farraye FA
    Gastrointest Endosc; 2019 Dec; 90(6):881-892. PubMed ID: 31526811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De Novo Colitis Associated With Rituximab in 21 Patients at a Tertiary Center.
    Eckmann JD; Chedid V; Quinn KP; Bonthu N; Nehra V; Raffals LE
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):252-253. PubMed ID: 30905719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-associated colitis.
    Barreiro Alonso E; Álvarez Álvarez A; Tojo González R; de la Coba Ortiz C
    Gastroenterol Hepatol; 2019 Apr; 42(4):251-252. PubMed ID: 29884483
    [No Abstract]   [Full Text] [Related]  

  • 10. Gastrointestinal endoscopy and mucosal biopsy in the first year of life: indications and outcome.
    Volonaki E; Sebire NJ; Borrelli O; Lindley KJ; Elawad M; Thapar N; Shah N
    J Pediatr Gastroenterol Nutr; 2012 Jul; 55(1):62-5. PubMed ID: 22210413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
    Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
    Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
    BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
    D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
    Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
    Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
    World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients.
    Shah N; Tan HL; Sebire N; Suri R; Leuven K
    Pediatr Pulmonol; 2013 Dec; 48(12):1181-9. PubMed ID: 23825099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection.
    Qureini A; Asif S; Harry S; Madhusudhana S
    Am J Case Rep; 2019 Sep; 20():1394-1397. PubMed ID: 31541071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases.
    Malpica Castillo LE; Palmer S; Zhu A; Deal AM; Chen SL; Moll S
    Am J Hematol; 2020 May; 95(5):E117-E120. PubMed ID: 32017201
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.
    Lebel E; Ben-Yehuda D; Bohbot E; Dranitzki Z; Shalit M; Tal Y
    J Allergy Clin Immunol Pract; 2016; 4(5):1000-2. PubMed ID: 27329468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.